Osteoclast inhibitors for knee conditions
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
1. A method of treating a normal joint space knee pain comprising administering an inhibitor of osteoclast activity to a person suffering from the normal joint space knee pain, wherein the inhibitor of osteoclast activity is olpadronic acid, alendronic acid, or incadronic acid.
2. The method of claim 1 , wherein the person has a pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS.
3. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice within two months.
4. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered about every three months, or more frequently.
5. The method of claim 1 , wherein the patient experiences pain relief within about three months after the inhibitor of osteoclast activity is administered to the patient.
6. The method of claim 5 , wherein the patient experiences pain relief at least 24 hours after the inhibitor of osteoclast activity is administered to the patient.
7. The method of claim 1 , wherein the pain is associated with inflammatory or musculoskeletal pain.
8. The method of claim 1 , wherein the inhibitor of osteoclast activity is olpadronic acid.
9. The method of claim 8 , wherein the olpadronic acid is administered orally or intravenously.
10. The method of claim 8 , wherein the olpadronic acid is administered daily, weekly, or monthly.
11. The method of claim 10 , wherein about 1000 mg to about 2000 mg of olpadronic acid is administered.
12. The method of claim 10 , wherein about 0.5 mg to about 200 mg of olpadronic acid is orally administered per day.
13. The method of claim 8 , wherein olpadronic acid is administered at least twice within two months.
14. The method of claim 1 , wherein the inhibitor of osteoclast activity is alendronic acid.
15. The method of claim 14 , wherein the alendronic acid is administered orally or intravenously.
16. The method of claim 14 , wherein the alendronic acid is administered daily, weekly, or monthly.
17. The method of claim 16 , wherein about 1 mg to about 50 mg of alendronic acid is orally administered per day.
18. The method of claim 16 , wherein about 30 mg to about 300 mg of alendronic acid is orally administered per week.
19. The method of claim 16 , wherein about 100 mg to about 1200 mg of alendronic acid is orally administered per month.
20. The method of claim 14 , wherein the alendronic acid is administered orally in a solid or a liquid form.
21. The method of claim 1 , wherein the inhibitor of osteoclast activity is incadronic acid.
22. The method of claim 21 , wherein the incadronic acid is administered orally or intravenously.
23. The method of claim 21 , wherein the incadronic acid is administered daily, weekly, or monthly.
24. The method of claim 23 , wherein about 1 mg to about 20 mg of incadronic acid is administered.
25. The method of claim 21 , wherein the incadronic acid is administered at least two times within two months.
26. The method of claim 21 , wherein the incadronic acid is administered at least three times within three months.
27. The method of claim 1 , wherein the osteoclast inhibitor is administered in a salt form.
28. The method of claim 1 , wherein the patient experiences a reduction in pain intensity—when using a 100 mm visual analog scale—of at least about 5.
29. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice over a period of at least four weeks.
30. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered once weekly for at least two weeks.